Data from a retrospective multicenter study, along with a review of previous trials, supported the real-world utility of ...

As the first IL-5-targeting monoclonal antibody in late-stage trials ... However, biologics like Dupixent (dupilumab) have paved the way for a new treatment paradigm, targeting specific ...

Chronic obstructive pulmonary disease (COPD) is a manifestation of structural violence, the process through which societies ...

Dupixent, or Dupilumab, is an FDA-approved monoclonal antibody for the treatment of eosinophilic esophagitis, or EoE, due to esophageal inflammation. It works on the mechanism of inhibiting IL-4 and ...

Dr. Yancopoulos and his team have used VelocImmune technology to create a substantial proportion of all original, FDA-approved or authorized fully human monoclonal antibodies. This includes Dupixent ...

Among other topics, Hudson discussed the success of Dupixent (dupilumab), highlighting ... to increase competition with the anti-OX40L monoclonal antibody (mAb) amlitelimab, which is currently ...

Dupilumab: A monoclonal antibody that inhibits interleukin-4 and interleukin-13 signaling, used to treat various allergic conditions. This Nature Research Intelligence Topic summary is one of ...

Sanofi and Regeneron’s Dupixent (dupilumab) has already built a ... an ICOS agonist monoclonal antibody, currently in early phase 1/2 development as monotherapy and in combination with an ...